BioXcel Therapeutics Enters Twelfth Amendment To Credit Agreement On August 10, 2026 - SEC Filing
BTAI•Credit agreement amendment and liquidity covenant
BioXcel Therapeutics Inc. entered the twelfth amendment to its credit agreement on August 10, 2026, according to an SEC filing.
The lenders reduced the minimum liquidity covenant to $3 million from $6.25 million.
Repayment or alternative capital solutions required by August 21
The company was required to enter agreements by August 21, 2026, to repay obligations or pursue alternative capital solutions, the filing said.
